Microtubule‐Targeting Chemotherapy Causes Mitochondrial Dysfunction in Heart and Skeletal Muscle
Authors: Ramos Sofhia V , Hughes Meghan C , Perry Christopher G. R. 
Published: November 2023

RATIONALEA variety of chemotherapies are associated with muscle dysfunction but the mechanisms are poorly understood. Emerging evidence suggests doxorubicin (DNA targeted chemotherapy) impairs mitochondrial respiration and increases H2O2 emission. However, whether other chemotherapies create similar mitochondrial dysfunctions in muscle is unknown. An emerging model proposes that microtubules can inhibit mitochondrial ADP import/ATP export by blocking outer membrane voltage‐dependent anion channels (VDAC). We hypothesized that microtubule‐targeting chemotherapies (taxol, microtubule stabilizer; vinblastine, microtubule destabilizer) may alter ADP control of oxidative phosphorylation by changing VDAC‐permeability to ADP. We also hypothesized that these chemotherapies would alter mitochondrial H2O2 emission considering ADP suppresses H2O2 emission from mitochondria during oxidative phosphorylation.METHODSMitochondrial ADP‐stimulated respiration and suppression of H2O2 emission were assessed in permeabilized muscle fibres from skeletal muscle (soleus, extensor digitorum longus; EDL) and heart left ventricle following incubation with taxol and vinblastine for 2 and 1hr respectfully, at 4°C.RESULTSDiverse responses were observed with both microtubule stabilizing (taxol) and destabilizing (vinblastine) drugs. However, a consistent pattern emerged in heart whereby the stabilizer taxol decreased respiration (5mM ADP: control, 195.5 ± 33.6 pmol/s/mg w.w., taxol, 112.5 ± 19.6 pmols/s/mg w.w., p= 0.05) while the destabilizer vinblastine had no effect. Both stabilizer and destabilizer decreased the ability of ADP to suppress H2O2 (taxol, 15 mM (p=0.03) and 100mM (p=0.02) ADP; vinblastine, 15mM to 500mM (p=0.01) ADP). No alterations were observed in succinate‐stimulated H2O2 emission protocols, demonstrating that the responses in heart were surprisingly substrate‐specific. In EDL, ADP‐stimulated respiration was increased at submaximal [ADP] with destabilizer (250mM ADP: control, 15.29 ± 2.10, vinblastine, 22.75 ± 2.81 pmol/min/mg d.w., p=0.05) but did not change with stabilizer. Both drugs decreased ADP‐suppression of H2O2 emission (with succinate) between 50mM to 500mM ADP (p=0.01). In soleus, ADP‐stimulated respiration and ADP‐suppression of H2O2 did not change with either drug.CONCLUSIONS AND DISCUSSIONHeart appears to be sensitive to microtubule‐targeted chemotherapy treatments as ADP‐stimulated respiration and suppression of H2O2 were impaired. Oxidative soleus may be more resistant to alteration in microtubule structure as ADP‐stimulated respiration and suppression of H2O2 did not change. In contrast, glycolytic EDL responded divergently to the destabilizer whereby ADP‐stimulated respiration was increased despite reduced ADP‐suppression of H2O2, whereas the stabilizer had no effect on respiration but also reduced ADP‐suppression of H2O2. Collectively, microtubule‐stabilizing and destabilizing compounds inhibit ADP control of mitochondrial bioenergetics in heart and glycolytic skeletal muscle. Subsequent experiments will determine how these responses are related to microtubule‐VDAC binding and muscle functional capacities.Support or Funding InformationFunding was provided to C.G.R.P. by National Science and Engineering Research Council (#436138‐2013) with infrastructure supported by Canada Foundation for Innovation, Ontario Research Fund and the James H. Cummings Foundation. S.V.R is supported by an OGS scholarship